Akero drug reverses liver scarring in study of severe MASH patients

Akero Therapeutics reported Monday strong results from a nearly two-year, placebo-controlled study showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by the liver disease known as MASH.

After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse, compared to 15% of participants randomized to a placebo. 

Patients with cirrhosis due to MASH have a severe form of the disease with few treatment options outside of a liver transplant. Once MASH progresses to cirrhosis, median survival is about five years, three times shorter than for patients with moderate, or mid-stage, MASH.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

A new breakthrough in the treatment of severe liver scarring has been discovered in a recent study using the drug Akero. The study found that Akero was able to reverse liver scarring, also known as fibrosis, in patients with severe non-alcoholic steatohepatitis (NASH).

NASH is a serious form of fatty liver disease that can lead to liver scarring and eventually liver failure if left untreated. Currently, there are limited treatment options available for NASH patients, making this new discovery with Akero all the more significant.

The study, which was conducted on a group of severe NASH patients, showed promising results with Akero. Not only was the drug able to reverse liver scarring, but it also improved liver function and reduced inflammation in the liver.

These findings have the potential to revolutionize the treatment of NASH and offer hope to the millions of individuals suffering from this debilitating disease. Further research is needed to confirm these results and determine the long-term effects of Akero, but this initial study is certainly a promising step in the right direction.

With more research and development, Akero could become a game-changer in the fight against liver scarring and NASH. Stay tuned for more updates on this groundbreaking discovery.

Tags:

1. Akero drug
2. liver scarring
3. MASH patients
4. liver disease treatment
5. liver fibrosis reversal
6. liver health study
7. severe liver conditions
8. medical research findings
9. liver scarring treatment
10. Akero pharmaceuticals

#Akero #drug #reverses #liver #scarring #study #severe #MASH #patients